tirzepatide for endometriosis Organon abandons pain drug development after trial failure GLP-1 in Endometriosis: What We

Per publicly available announcements, the FDA issued more than 50 warning letters to GLP-1 compounders and manufacturers in September 2025, followed by 30 additional warning letters to telehealth firms in early 2026, targeting false or misleading marketing claims about compounded GLP-1 products

& Zachmann, M

Before the study began, all participants had magnetic resonance imaging (MRI) to evaluate brain structure and volumes, glucose metabolism with PET scans and other tests looking at memory, comprehension, language and spatial orientation

San Francisco clients appreciate that the best weight loss clinic approach treats them as unique individuals rather than generic cases

Real medicine, real oversight.